We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Summit Therapeutics Plc | LSE:SUMM | London | Ordinary Share | GB00BN40HZ01 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.50 | 18.00 | 23.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
28/3/2019 06:51 | Should be a Good day ahead today | kirk 6 | |
28/3/2019 06:35 | Hopefully we are in the right place at the right time! "Lord O'Neill said that since then there had been empty words from global policy makers and that he was coming round to the idea of, in effect, nationalising part of the pharmaceutical industry." | waterloo01 | |
28/3/2019 00:33 | Summit Therapeutics well backed for next phase of development 11:54 27 Mar 2019 | football | |
27/3/2019 18:46 | Agreed nice buys on the Nasdaq and a higher price ! Should be a good day tomorrow on our side | kirk 6 | |
27/3/2019 18:14 | Markets aside, this should recover to $2.00 base and onto $2.50/$3.00. Lots of II interest and much better volume on Nasdaq | waterloo01 | |
27/3/2019 18:10 | Full transcript including Q&A. Conference Call Participants Hartaj Singh - Oppenheimer & Company Tim Chiang - BTIG Joseph Hedden - Rx Securities Yun Zhong - Janney Gary Waanders - Bryan Garnier Julie Simmonds - Panmure Gordon Dewey Steadman - Canaccord | waterloo01 | |
27/3/2019 17:30 | Abstracts due next week. | gooosed | |
27/3/2019 14:13 | Hi waterloo01 Thanks for your post I did not feel too grumpy this morning but I did leave the house at 7.00 to take the car for a service. I was going to add an edit to try & look more positive in that Summit have in their favour strong underlying science with great potential & which I believe both will get to market & I do concur with the rest of your comments. | chrisatrdg | |
27/3/2019 13:37 | Get out the wrong side of bed today Chris? More to the point, they have an excellent track record recently in gaining grants and other such non dilutive funding, and also more recently at a premium with a billionaire backer, who is highly likely to continue investing. By the autumn, they will have a drug well on it's way through phase 3 in c.diff, a 2nd drug for gonorrhoea in phase 1/2, and likely a further two in key unmet areas entering initial trials. I think at that point, they will be establishing themselves as a unique multi therapy anti-biotic company, and a tasty morsel for someone! | waterloo01 | |
27/3/2019 13:05 | Todays RNS It is good to see a profit was made but a 'paper profit' due to it being based on releasing deferred revenue for which most of the cash has already been received.Progress is clearly being made but the 'Elephant in the room' is still that a fund raise will be required in order to extend the cash run way beyond January 2020 as detailed below.Until the funding issue is resolved I cannot see how the share price can significantly improve this year. Extract from the Notes to the Accounts: 'The Group is evaluating various options to finance its cash needs through a combination of some, or all, of the following: equity offerings, collaborations, strategic alliances, grants and clinical trial support from government entities, philanthropic, non-government and not-for-profit organisations and patient advocacy groups, debt financings, and marketing, distribution or licensing arrangements. Whilst the Group believes that funds would be available in this manner before the end of January 2020, there can be no assurance that the Group will be able to generate funds, on terms acceptable to the Group, on a timely basis or at all, which would impact the Group’s ability to continue as a going concern. The failure of the Group to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Group’s business, results of operations and financial condition.' | chrisatrdg | |
27/3/2019 13:03 | Excellent call, esp the Q&A. Some interesting news about presentations embargoed until next week. Next targets!! | waterloo01 | |
25/3/2019 15:22 | It seems no news is good news with this share | football | |
25/3/2019 15:00 | All these articles seem extremely up near for Summ however the more articles they get posted the lower the share price goes. Back in to the debths again now from hitting 34p a few weeks ago | kirk 6 | |
25/3/2019 14:28 | Up beat article: Summit Therapeutics Has Started Attracting Institutional Investors Again: alpha.com/article/42 | chrisatrdg | |
22/3/2019 05:58 | Don't have time today but looks like some new slides in here. | waterloo01 | |
19/3/2019 12:54 | Thats me out for a 16% loss. GLA | volsung | |
18/3/2019 16:18 | Summit Therapeutics PLC (LON:SUMM) (NASDAQ:SMMT), a leader in new mechanism antibiotic innovation, has announced that its management will present at two upcoming conferences: Superbugs & Superdrugs 2019: The Development of Precision Antibiotics: Agents Designed to Meet the Demands of Stewardship, on 18 March 2019 at 1:40pm GMT in London; and Oppenheimer 29th Annual Healthcare Conference: corporate presentation on 20 March 2019 at 2:10pm EDT in New York City. | football | |
14/3/2019 20:16 | Price seemed to have finished 2.10 on the Nasdaq about 33p | kirk 6 | |
14/3/2019 11:06 | Summit Therapeutics plc Summit Highlights Use Of Discuva Platform In Identifying New Mechanism Antibiotics Against Neisseria ... Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference -- N. Gonorrhoeae and ESKAPE Pathogens Identified as High Priority by the US CDC and the WHO | football | |
13/3/2019 08:13 | Shame in closed below $2.00 but holding strong today including a buy of 345k shares. Edit: wonder of it's part of a larger order? | waterloo01 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions